RJA
CNCE

Raymond James & Associates’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Raymond James & Associates’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,073
Closed -$102K – 3783
2019
Q4 		$102K Buy
+11,073
New +$78.5K ﹤0.01% 3476

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James & Associates's CNCE Position: Q1 2020 in Review

Raymond James & Associates sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2020, closing a stake of 11,073 shares — an estimated $102K sold.

Raymond James & Associates first reported a position in CNCE in Q4 2019 and held it in 1 quarter. The position peaked at $102K in Q4 2019. 79 funds tracked by Wall St. Rank hold CNCE as of Q1 2020.

  • Raymond James & Associates reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 11,073 Concert Pharmaceuticals, Inc. shares in Q1 2020, an estimated $102K.
  • Raymond James & Associates first reported a position in Concert Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Raymond James & Associates's Concert Pharmaceuticals, Inc. position peaked at $102K in Q4 2019.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.